Urothelial Carcinoma Treatment Market - Top Companies and Manufacturers

Companies Dominating the Urothelial Carcinoma Treatment Landscape

Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
GlaxoSmithKline plc
Novartis AG
Dendreon Pharmaceuticals LLC
Sanofi SA
F. Hoffmann-La-Roche AG
UroGen Pharma Ltd
Koninklijke Philips N.V.
Olympus Corporation
AstraZeneca PLC

Browse Key Market Insights with Data Illustration:

Urothelial Carcinoma Treatment Market Size & Share, Forecast Report 2036

In the News

Olympus Corporation announced a binding agreement to purchase London-based cloud-AI endoscopy business Odin Vision, which offers a wide range of commercially available computer-aided detection/diagnostic (CAD) solutions. With the agreement, Olympus is able to provide cutting-edge AI-powered solutions and data-driven insights that improve clinical and procedural procedures and change patient care.
Sanofi SA licensed an NK cell engager program from Innate's ANKETTM (Antibody-based NK Cell Engager Therapies) technology that targets B₇H₃. This extended partnership with Innate Pharma will enable Sanofi to have the option of including up to two more ANKETTM targets, and be in control of all development, manufacture, and marketing.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of urothelial carcinoma treatment is estimated at USD 1.44 Billion.

The urothelial carcinoma treatment market size was valued at USD 1.21 Billion in 2023 and is expected to cross USD 15.1 Billion by the end of 2036, registering more than 21.4% CAGR during the forecast period i.e., between 2024-2036. Raising funding for research and development to develop novel cancer therapies and the growing awareness about bladder diseases are the major factors driving the market growth.

North America is likely to dominate majority industry share by 2036, attributed to increasing frequency of urothelial carcinoma cancer in the region.

Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Dendreon Pharmaceuticals LLC, Sanofi SA, F. Hoffmann-La-Roche AG, UroGen Pharma Ltd, Koninklijke Philips N.V., Olympus Corporation, AstraZeneca PLC

Urothelial Carcinoma Treatment Market - Top Companies and Manufacturers

Companies Dominating the Urothelial Carcinoma Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What is the size of the urothelial carcinoma treatment market?

Why is the urothelial carcinoma treatment sector gaining traction in near future?

Which region accounted for the largest urothelial carcinoma treatment industry share?

Who are the major urothelial carcinoma treatment players?